Orthomod was granted FDA 510(k) clearance to market the new MOD-C cervical intervertebral implant family for the treatment of degenerative disc disease of the cervical spine from C2-T1. This milestone represents the clearance of a novel, permanent biomaterial composite for use in orthopedic and spine surgery.
CAMP (calcium-acrylic modified polymer) is a unique composite of an acrylic polymer and synthetic beta-tricalcium phosphate/hydroxyapatite (B-TCP/HA), and introduces a new material option for structural orthopedic implants. CAMP is designed with a broad range of potential applications in spine, reconstructive orthopedics, dentistry, sports medicine, and oncology.
The MOD-C implant family, planned for clinical launch in the second half of 2026, was developed to address the longstanding need for a cervical interbody device that provides immediate structural support while utilizing biphasic calcium phosphate incorporated into a microporous polymer matrix.
To evaluate the biological response, Orthomod assessed the MOD-C material in preclinical studies using an osseointegration model in both cortical and cancellous sites over a 26-week integration period.
The FDA clearance of MOD-C represents the first step in Orthomod’s broader platform strategy. The company is advancing additional products based on CAMP across multiple orthopedic, spine, and dental applications.
Orthomod was granted FDA 510(k) clearance to market the new MOD-C cervical intervertebral implant family for the treatment of degenerative disc disease of the cervical spine from C2-T1. This milestone represents the clearance of a novel, permanent biomaterial composite for use in orthopedic and spine surgery.
CAMP (calcium-acrylic modified...
Orthomod was granted FDA 510(k) clearance to market the new MOD-C cervical intervertebral implant family for the treatment of degenerative disc disease of the cervical spine from C2-T1. This milestone represents the clearance of a novel, permanent biomaterial composite for use in orthopedic and spine surgery.
CAMP (calcium-acrylic modified polymer) is a unique composite of an acrylic polymer and synthetic beta-tricalcium phosphate/hydroxyapatite (B-TCP/HA), and introduces a new material option for structural orthopedic implants. CAMP is designed with a broad range of potential applications in spine, reconstructive orthopedics, dentistry, sports medicine, and oncology.
The MOD-C implant family, planned for clinical launch in the second half of 2026, was developed to address the longstanding need for a cervical interbody device that provides immediate structural support while utilizing biphasic calcium phosphate incorporated into a microporous polymer matrix.
To evaluate the biological response, Orthomod assessed the MOD-C material in preclinical studies using an osseointegration model in both cortical and cancellous sites over a 26-week integration period.
The FDA clearance of MOD-C represents the first step in Orthomod’s broader platform strategy. The company is advancing additional products based on CAMP across multiple orthopedic, spine, and dental applications.
Copy to clipboard 
